Piqray Tablet
Product Images NDC 0078-0708

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Piqray (NDC 0078-0708). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Alpelisib Structural Formula (Byl719 01)

Chemical structure of alpelisib, the active ingredient in PIQRAY tablets. The diagram shows the molecular structure with detailed atom connectivity and stereochemistry.*

FDA Label Image

Figure 1: Progression Free Survival In Solar-1 (per Investigator Assessment Of Patients With A Pik3ca Tumor Mutation) (Byl719 02)

A Kaplan-Meier survival curve showing event-free probability (%) over time (months) comparing Alpelisib + Fulvestrant versus Placebo + Fulvestrant. The graph includes censoring times and a table below indicating the number of subjects at risk at different time points for each group.*

FDA Label Image

Principal Display Panel Ndc 0078-0708-02 Piqray® (alpelisib) Tablets 300 mg Daily Dose Take Two 150 mg Tablets Once Daily Rx Only Usual Dosage: Take Two 150 mg Tablets Once Daily With Food. Swallow Tablets Whole. Do Not Chew,crush, Or Split Tablets. See Prescribing Information For Complete Dosage Information. 28-day Supply Contains: Two 14-day Blister Packs Each Containing 28 Tablets Novartis (Byl719 03)

PIQRAY (alpelisib) tablets packaging label for 150 mg strength. The label shows 300 mg daily dose instructions to take two 150 mg tablets once daily. It includes manufacturer information (Novartis Pharma Stein AG, Switzerland), distributor (Novartis Pharmaceuticals Corporation), and a 28-day supply note with two 14-day blister packs containing 28 tablets. The label specifies oral use and storage instructions.*

FDA Label Image

Principal Display Panel Ndc 0078-0715-02 Piqray® (alpelisib) Tablets 250 mg Daily Dose Take One 200 mg Tablet And One 50 mg Tablet Once Daily Rx Only Usual Dosage: Take One 200 mg Tablet And One 50 mg Tablet Once Daily With Food. Swallow Tablets Whole. Do Not Chew, Crush, Or Split Tablets. See Prescribing Information For Complete Dosage Information. 28-day Supply Contains: Two 14-day Blister Packs Each Containing 28 Tablets: 200 mg 14 Tablets Per Pack 50 mg 14 Tablets Per Pack Novartis (Byl719 04)

PIQRAY (alpelisib) tablets packaging label showing a 250 mg daily dose regimen with instructions to take one 200 mg tablet and one 50 mg tablet once daily. The label includes dosage details, storage instructions, manufacturer Novartis Pharma Stein AG, Switzerland, and distributor Novartis Pharmaceuticals Corporation, New Jersey. The package contains a 28-day supply with two 14-day blister packs, each with 14 tablets of 200 mg and 14 tablets of 50 mg.*

FDA Label Image

Principal Display Panel Ndc 0078-0701-84 Piqray® (alpelisib) Tablets 200 mg Daily Dose Take One 200 mg Tablet Once Daily Rx Only Usual Dosage: Take One 200 mg Tablet Once Daily With Food. Swallow Tablets Whole. Do Not Chew, Crush, Or Split Tablets. See Prescribing Information For Complete Dosage Information. 28-day Supply Contains: One Blister Pack Containing 28 Tablets Novartis (Byl719 05)

PIQRAY 200 mg tablets packaging label for oral tablets containing 200 mg alpelisib. The label includes dosage instructions to take one 200 mg tablet once daily with food, storage guidelines, and a 28-day supply of 28 tablets per blister pack. Manufactured by Novartis Pharma Stein AG in Switzerland and distributed by Novartis Pharmaceuticals Corporation in New Jersey.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.